Concourse Financial Group Securities, Inc. Akouos, Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $1.64 Billion
  • Q3 2024

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 15, 2022
BUY
$2.6 - $5.16 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$2.46 - $5.2 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$4.16 - $9.08 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$7.65 - $11.38 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$9.93 - $13.59 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$11.87 - $15.96 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021
BUY
$13.87 - $21.04 $0 - $0
0 New
0 $0
Q4 2020

Feb 02, 2021
BUY
$17.03 - $22.45 $0 - $0
0 New
0 $0
Q3 2020

Nov 13, 2020
BUY
$19.3 - $26.92 $0 - $0
0 New
0 $0
Q2 2020

Aug 13, 2020
BUY
$22.0 - $22.5 $0 - $0
0 New
0 $0

About Akouos, Inc.

AKUS Quotes by TradingView
  • Ticker AKUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,929,000
  • Description
  • Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therap...
More about AKUS
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email